Is there any stock notes I can subscribe to for about $300 a year that will confirm my $mnkd bias and tell me this co. is a $50 stock while also affirming my notion that afrezza isn't a bust after 5 yrs with Nrx 289
#MNKD Certification from Deloitte Touche in recent 10Q says " the Company’s available cash resources and continuing cash needs raise substantial doubt about its ability to continue as a going concern."
$ARNA March 2017 Split adjusted 24.5M shares March 2018 47.78M shares after recent offering. 49.05M shares if Underwriters exercise option. Over 100% dilution in year.
$arna bookrunner Cantor raises pt though only drug a sales disaster has patent challenges, pipeline is understudied, for crowded markets, feeble and years from trials completion and submission to FDA. How strange. #stocks#pharma#biotech
$arna has divulged patent issues may effect commercialization of delayed Etrasimod. Many trials left for this 14year old research compound #stocks#pharma#biotech#Biotechnology